Display options
Cite
Kacew AJ, Dharaneeswaran H, Starrett GJ, et al. Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget. 2020;11(47):4401-4410doi: 10.18632/oncotarget.27823.
Kacew, A. J., Dharaneeswaran, H., Starrett, G. J., Thakuria, M., LeBoeuf, N. R., Silk, A. W., DeCaprio, J. A., & Hanna, G. J. (2020). Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget, 11(47), 4401-4410. https://doi.org/10.18632/oncotarget.27823
Kacew, Alec J, et al. "Predictors of immunotherapy benefit in Merkel cell carcinoma." Oncotarget vol. 11,47 (2020): 4401-4410. doi: https://doi.org/10.18632/oncotarget.27823
Kacew AJ, Dharaneeswaran H, Starrett GJ, Thakuria M, LeBoeuf NR, Silk AW, DeCaprio JA, Hanna GJ. Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget. 2020 Nov 24;11(47):4401-4410. doi: 10.18632/oncotarget.27823. eCollection 2020 Nov 24. PMID: 33315984; PMCID: PMC7720777.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2020 Nov 24;11(47):4401-4410. doi: 10.18632/oncotarget.27823. eCollection 2020 Nov 24.

Predictors of immunotherapy benefit in Merkel cell carcinoma.

Oncotarget

Alec J Kacew, Harita Dharaneeswaran, Gabriel J Starrett, Manisha Thakuria, Nicole R LeBoeuf, Ann W Silk, James A DeCaprio, Glenn J Hanna

Affiliations

  1. GJS Associated with Laboratory of Cellular Oncology, CCR/NCI, Bethesda, MD, USA.
  2. Dana-Farber Cancer Institute, Boston, MA, USA.
  3. These authors contributed equally to this work.

PMID: 33315984 PMCID: PMC7720777 DOI: 10.18632/oncotarget.27823

Abstract

Merkel cell carcinoma is a rare cancer for which immune checkpoint blockade is standard-of-care for recurrent/metastatic disease. However, not all patients benefit from immunotherapy. A greater understanding of molecular mechanisms and predictive biomarkers are unmet needs. We retrospectively analyzed electronic health records and next-generation sequencing data of 45 patients treated at our institution from 2013 to 2020 to understand clinical and genomic correlates of benefit from immunotherapy. Our cohort predominantly included individuals with stage III disease at primary disease diagnosis and individuals with stage IV disease at recurrent/metastatic disease diagnosis. Most received immunotherapy as first-line treatment. 43% experienced objective response (median duration of response 24.2 months, 95% confidence interval 8.8-not reached). Median overall survival was 15.5 months (95% confidence interval 9.0-28.7) (median follow-up 25.2 months). Less advanced stage at primary disease diagnosis and shorter disease-free interval between completion of initial treatment and recurrence were each associated with greater odds of response (odds ratio of 0.06,

Copyright: © 2020 Kacew et al.

Keywords: Merkel cell carcinoma; cancer; genomics; immunotherapy; precision medicine

Conflict of interest statement

CONFLICTS OF INTEREST AJK receives research support from the Pritzker School of Medicine and from the American Society of Hematology. Dr. Silk has received research funding (to the institution) from B

References

  1. Science. 2018 Feb 16;359(6377):770-775 - PubMed
  2. Eur J Cancer. 2017 Jan;71:53-69 - PubMed
  3. J Clin Oncol. 2019 Mar 20;37(9):693-702 - PubMed
  4. J Exp Clin Cancer Res. 2019 Oct 22;38(1):424 - PubMed
  5. Oncogene. 2002 Nov 28;21(54):8334-9 - PubMed
  6. J Am Acad Dermatol. 2018 Mar;78(3):457-463.e2 - PubMed
  7. Cancers (Basel). 2019 Apr 02;11(4): - PubMed
  8. JCI Insight. 2016 Nov 17;1(19):e87062 - PubMed
  9. Lancet Oncol. 2017 Jul;18(7):895-903 - PubMed
  10. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  11. Arch Pathol Lab Med. 2017 Jun;141(6):751-758 - PubMed
  12. J Am Acad Dermatol. 2019 Apr;80(4):1154-1156 - PubMed
  13. J Mol Diagn. 2020 Apr;22(4):476-487 - PubMed
  14. J Immunother Cancer. 2018 Jan 19;6(1):7 - PubMed
  15. JAMA Dermatol. 2017 Nov 1;153(11):1166-1169 - PubMed
  16. Apoptosis. 2006 Sep;11(9):1513-24 - PubMed
  17. Clin Cancer Res. 2019 Oct 1;25(19):5961-5971 - PubMed
  18. Oral Oncol. 2018 Oct;85:29-34 - PubMed
  19. J Immunol. 2012 Jul 15;189(2):558-66 - PubMed
  20. JAMA Dermatol. 2016 Sep 1;152(9):1001-7 - PubMed
  21. Ann Surg Oncol. 2016 Oct;23(11):3564-3571 - PubMed
  22. J Immunother Cancer. 2020 May;8(1): - PubMed
  23. Cancer Immunol Res. 2015 Apr;3(4):345-55 - PubMed
  24. J Immunol. 2004 Aug 15;173(4):2462-9 - PubMed
  25. Genome Med. 2020 Mar 18;12(1):30 - PubMed
  26. J Natl Cancer Inst. 2009 Jul 1;101(13):938-45 - PubMed
  27. Lancet Oncol. 2015 Oct;16(13):e498-509 - PubMed
  28. J Cancer Res Clin Oncol. 2018 Jul;144(7):1301-1308 - PubMed
  29. J Immunol. 2005 Jun 15;174(12):7516-23 - PubMed

Publication Types